PET imaging for kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new PET imaging agent that may help detect and evaluate kidney masses suspected to be kidney cancer, including early or recurring cases. It could help doctors better understand the tumor before deciding on treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a kidney mass that needs checking, suspected kidney cancer, known clear cell kidney cancer, or a suspected recurrence of kidney cancer.
- You are expected to live at least 6 more months.
- If you could become pregnant, you must use effective birth control for at least 35 days after the imaging test.
- You have not had chemotherapy, radiation, or immunotherapy in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new PET/CT scan that uses a special tracer to find clear cell kidney cancer. If you are scheduled for kidney tumor removal, this scan may help your surgeon see the cancer more clearly before surgery.
This trial uses a special imaging scan (68Ga-C1 PET/CT) to see kidney cancer more clearly. It helps doctors find and understand clear cell renal cell carcinoma, a common type of kidney cancer.
This study tests a special imaging agent (89Zr-TLX250) to help doctors see clear cell kidney cancer during PET/CT scans. It is for people in China who have a single small kidney mass and are already scheduled for surgery to remove it.
This study tests a new kind of PET scan that might better detect kidney cancer. It involves an injection of a special imaging agent and a scan to see if the cancer shows up clearly.
This study tests a new imaging method that uses a special tracer to find solid tumors in the body. It may help doctors see tumors more clearly and guide treatment.
This Phase 1 study tests whether a special PET/CT scan drug ([18F]PT2385) can help doctors see kidney cancer and related tumors. It may help guide diagnosis and treatment decisions, especially in people planning surgery or starting belzutifan.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.